{
  "abstract": "This perspective describes Registry Pharmacology, a translational framework that integrates spontaneous adverse drug reaction (ADR) reporting with prescribing data, physicochemical descriptors and polypharmacology, to move beyond signal detection towards mechanistic interpretation of real world drug safety. The framework rests on three pillars. First, exposure normalisation standardises ADR reporting frequency to prescriptions using national datasets, contextualising spontaneous ADR reporting relative to prescribing volume, without estimating comparative risks among exposed patients. Second, clinically achievable pharmacology filtering restricts off-target interactions to those occurring at or below clinically relevant Cmax, giving mechanistic insights. Third, physicochemical integration provides interpretive context for tissue specific ADR patterns. Across studies spanning oncology to respiratory medicine, the framework has consistently generated pharmacologically coherent, mechanistically plausible hypotheses for ADR divergence. Interpretable machine learning yielded ROC AUC values up to 0.94 for ADR-category classification, although discrimination alone does not establish reliable signal detection or prospective clinical utility. Acknowledged limitations include the inherent constraints of spontaneous reporting systems e.g., underreporting, notoriety bias, confounding by indication, incomplete pharmacology databases, largely unaddressed polypharmacy and drug drug interactions, and the hypothesis-generating rather than causal inference character of the methodology. Registry Pharmacology may offer a translational framework for converting pharmacovigilance data into pharmacologically interpretable intelligence. As data infrastructure, regulatory need for mechanistic evidence and interpretable AI capabilities matures, this framework may contribute to supporting a transition from reactive epidemiological surveillance to prospective, mechanistically informed drug safety science.",
  "abstract_shown": true,
  "affiliations": [
    "chool of Pharmacy, School of Health Sciences, College of Medicine and Health, University of Birmingham, Edgbaston, United Kingdom"
  ],
  "article_type": null,
  "arxiv": null,
  "author_total": 2,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Vicky Cheng"
    },
    {
      "affs": [
        0
      ],
      "name": "Alan M. Jones"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/49nyy8b9bpbxw.bib",
  "cited_by": 0,
  "doi": "10.3389/fdsfr.2026.1992258",
  "fulltext_url": "https://www.frontiersin.org/articles/10.3389/fdsfr.2026.1992258/full",
  "id": "49nyy8b9bpbxw",
  "issns": [
    "2674-0869"
  ],
  "landing_url": "https://doi.org/10.3389/fdsfr.2026.1992258",
  "language": "en",
  "licence": "CC-BY",
  "licence_label": "CC BY",
  "licence_source": "journal",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "lcc",
      "RM1-950"
    ]
  ],
  "openalex": null,
  "pdf_url": null,
  "pmcid": null,
  "pmid": null,
  "published": "2026-11-16",
  "publisher": "Frontiers Media S.A.",
  "ris": "https://research.draconitic.com/paper/49nyy8b9bpbxw.ris",
  "sources": [
    {
      "first_seen": "2026-11-16T15:21:14Z",
      "native_id": "077d3f69da1642c9adeeff009fae8119",
      "source": "doaj",
      "url": "https://doi.org/10.3389/fdsfr.2026.1992258"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "lcc:RM1-950",
      "subfield": "pharmacology-toxicology"
    }
  ],
  "title": "From signal to mechanism: registry pharmacology and the future of translational pharmacovigilance",
  "title_text": "From signal to mechanism: registry pharmacology and the future of translational pharmacovigilance",
  "type": "peer-reviewed",
  "updated_at": "2026-11-16T15:21:14Z",
  "url": "https://research.draconitic.com/paper/49nyy8b9bpbxw",
  "venue": "Frontiers in Drug Safety and Regulation",
  "versions": []
}